Evolent Health (EVH) Stock Forecast & Price Target

$12.67 -0.08 (-0.63%)

(As of 11/14/2024 ET)

Evolent Health - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 12 Analyst Ratings

Sell
0

Hold
1

Buy
11

Based on 12 Wall Street analysts who have issued ratings for Evolent Health in the last 12 months, the stock has a consensus rating of "Buy." Out of the 12 analysts, 1 has given a hold rating, 10 have given a buy rating, and 1 has given a strong buy rating for EVH.

Consensus Price Target

$29.50
132.83% Upside

According to the 12 analysts' twelve-month price targets for Evolent Health, the average price target is $29.50. The highest price target for EVH is $45.00, while the lowest price target for EVH is $16.00. The average price target represents a forecasted upside of 132.83% from the current price of $12.67.

EVH Analyst Ratings Over Time

Type	Current Forecast 11/16/23 to 11/15/24	1 Month Ago 10/17/23 to 10/16/24	3 Months Ago 8/18/23 to 8/17/24	1 Year Ago 11/16/22 to 11/16/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	10 Buy rating(s)	12 Buy rating(s)	12 Buy rating(s)	7 Buy rating(s)
Hold	1 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$29.50	$39.91	$41.10	$47.00
Forecasted Upside	132.83% Upside	50.49% Upside	50.11% Upside	59.54% Upside
Consensus Rating	Buy	Buy	Buy	Moderate Buy

7 Cheap and Good Stocks (Ad)

It's the holy grail of the stock market... Stocks that trade for pennies on the dollar yet have the potential to skyrocket for monster gains. Well, we've uncovered SEVEN such stocks.

Simply follow this link and claim your copy today at no charge whatsoever.

EVH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

EVH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Evolent Health Stock vs. The Competition

Type	Evolent Health	Computer and Technology Companies	S&P 500
Consensus Rating Score	3.00	2.67	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	132.83% Upside	564.68% Upside	8.87% Upside
News Sentiment Rating	Neutral News See Recent EVH News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/13/2024	Citigroup 3 of 5 stars		Lower Target	Buy ➝ Buy	$33.00 ➝ $21.00	+64.06%
11/12/2024	Royal Bank of Canada 4 of 5 stars		Reiterated Rating	Outperform ➝ Outperform	$20.00 ➝ $20.00	+35.04%
11/11/2024	Barclays 3 of 5 stars		Lower Target	Overweight ➝ Overweight	$39.00 ➝ $19.00	+37.68%
11/8/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$45.00 ➝ $34.00	+129.57%
11/8/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Garro Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$38.00 ➝ $16.00	-34.93%
10/11/2024	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$35.00	+30.60%
625,000% Gain (Ad) Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz. >> Dive into the Workshop Here
8/27/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Singh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $33.00	+5.26%
8/19/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$36.00 ➝ $45.00	+60.77%
8/9/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Market Outperform ➝ Market Outperform	$34.00 ➝ $31.00	+48.11%
5/10/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$44.00 ➝ $41.00	+70.41%
1/9/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
11/16/2023	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
10/16/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$46.00	+64.29%
8/14/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$47.00	+65.03%
2/23/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$40.00 ➝ $45.00	+31.31%
1/30/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$57.00 ➝ $59.00	+88.68%
1/6/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$44.00 ➝ $51.00	+93.55%
11/18/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$52.00 ➝ $57.00	+138.89%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 04:58 AM ET.

EVH Forecast - Frequently Asked Questions

: According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Evolent Health is $29.50, with a high forecast of $45.00 and a low forecast of $16.00.
: 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evolent Health in the last twelve months. There is currently 1 hold rating, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" EVH shares.
: According to analysts, Evolent Health's stock has a predicted upside of 132.83% based on their 12-month stock forecasts.
: Over the previous 90 days, Evolent Health's stock had 1 upgrade and 1 downgrade by analysts.
: Evolent Health has been rated by research analysts at Barclays, Citigroup, JPMorgan Chase & Co., KeyCorp, Oppenheimer, Royal Bank of Canada, Stephens, and Truist Financial in the past 90 days.
: Analysts like Evolent Health more than other "computer and technology" companies. The consensus rating for Evolent Health is Buy while the average consensus rating for "computer and technology" companies is Moderate Buy. Learn more on how EVH compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Has Trump Finally Gone Too Far? (Ad)

Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.

This page (NYSE:EVH) was last updated on 11/15/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evolent Health (EVH) Stock Forecast & Price Target